PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options

Core Viewpoint - PCI Biotech has concluded its external evaluation of a new bioprocessing technology with no prospects for further collaboration, leading to the discontinuation of all R&D operations due to limited interest [1]. Group 1: Company Operations - The company has explored various strategic alternatives in recent months, including a potential merger or a structured wind-up of operations [2]. - All R&D operations will be discontinued as the company's limited operations were contingent upon sustained external interest [1]. Group 2: Financial Position - The liquidity position of PCI Biotech remains critical, with no assurance that additional financing can be secured, raising significant doubts about the company's ability to continue as a going concern [3].